<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010357</article-id><article-id pub-id-type="publisher-id">ACM-38261</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_41382585.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  缺氧诱导因子-2在头颈部肿瘤中的研究进展
  Research Progress of Hypoxia Inducible Factor-2 in Head and Neck Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>钦</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>山东临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff2"><addr-line>山东第一医科大学(山东省医学科学院)，山东 泰安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2367</fpage><lpage>2371</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    缺氧诱导因子-2 (Hypoxia Inducible Factor-2, HIF-2)作为缺氧诱导因子家族中的一员，与多种恶性肿瘤发生发展密切相关。头颈部肿瘤是一组包括鼻咽癌、喉癌、口腔癌、甲状腺癌等临床常见的恶性肿瘤，具有高死亡率及高致残率的特点。近年来研究表明HIF-2与头颈部肿瘤关系密切。本文就HIF-2的结构、调控及其与头颈部肿瘤进展的关系作一综述。
    Hypoxia inducible factor-2 (HIF-2), as a member of the hypoxia inducible factor family, is closely related to the occurrence and development of various malignant tumors. Head and neck cancer are a group of clinical common malignant tumors, including nasopharyngeal carcinoma, laryngeal cancer, oral cancer, thyroid cancer and so on. Recent studies have shown that HIF-2 is closely related to head and neck tumors. This article reviews the structure and regulation of HIF-2 and its relationship with the progression of head and neck tumors. 
  
 
</p></abstract><kwd-group><kwd>缺氧诱导因子-2，头颈部肿瘤，恶性肿瘤, Hypoxia Inducible Factor-2</kwd><kwd> Head and Neck Tumors</kwd><kwd> Malignant Tumors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>缺氧诱导因子-2 (Hypoxia Inducible Factor-2, HIF-2)作为缺氧诱导因子家族中的一员，与多种恶性肿瘤发生发展密切相关。头颈部肿瘤是一组包括鼻咽癌、喉癌、口腔癌、甲状腺癌等临床常见的恶性肿瘤，具有高死亡率及高致残率的特点。近年来研究表明HIF-2与头颈部肿瘤关系密切。本文就HIF-2的结构、调控及其与头颈部肿瘤进展的关系作一综述。</p></sec><sec id="s2"><title>关键词</title><p>缺氧诱导因子-2，头颈部肿瘤，恶性肿瘤</p></sec><sec id="s3"><title>Research Progress of Hypoxia Inducible Factor-2 in Head and Neck Tumors<sup> </sup></title><p>Wei Gao<sup>1</sup>, Qin Li<sup>2*</sup></p><p><sup>1</sup>Shandong First Medical University (Shandong Academy of Medical Sciences), Tai’an Shandong</p><p><sup>2</sup>Linyi City People Hospital, Linyi Shandong</p><p><img src="//html.hanspub.org/file/24-1571618x4_hanspub.png" /></p><p>Received: Oct. 5<sup>th</sup>, 2020; accepted: Oct. 20<sup>th</sup>, 2020; published: Oct. 27<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/24-1571618x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Hypoxia inducible factor-2 (HIF-2), as a member of the hypoxia inducible factor family, is closely related to the occurrence and development of various malignant tumors. Head and neck cancer are a group of clinical common malignant tumors, including nasopharyngeal carcinoma, laryngeal cancer, oral cancer, thyroid cancer and so on. Recent studies have shown that HIF-2 is closely related to head and neck tumors. This article reviews the structure and regulation of HIF-2 and its relationship with the progression of head and neck tumors.</p><p>Keywords:Hypoxia Inducible Factor-2, Head and Neck Tumors, Malignant Tumors</p><disp-formula id="hanspub.38261-formula34"><graphic xlink:href="//html.hanspub.org/file/24-1571618x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/24-1571618x8_hanspub.png" /> <img src="//html.hanspub.org/file/24-1571618x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>头颈部肿瘤是临床上常见的肿瘤类型之一，其解剖结构复杂且早期发病症状隐匿，具有高死亡率及高致残率的特点 [<xref ref-type="bibr" rid="hanspub.38261-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38261-ref2">2</xref>]。虽然随着手术治疗、放射治疗及化学药物治疗等方法不断完善及改进，但其晚期患者生存率及生存质量仍不令人满意。因此，探究头颈部肿瘤发生发展机制，寻找新的、更为有效的诊断和治疗策略，对于头颈部肿瘤治疗有重大意义。近年来研究表明缺氧诱导因子-2 (Hypoxia Inducible Factor-2, HIF-2)作为HIF家族中的重要一员，与头颈部肿瘤发生发展关系密切。本文复习近年来国内外相关文献，就HIF-2的结构、调控及其与头颈部肿瘤进展的关系作一综述，以期为头颈部肿瘤防治提供一定的理论参考。</p></sec><sec id="s6"><title>2. HIF-2概述</title><sec id="s6_1"><title>2.1. HIF-2结构</title><p>HIF-2由活性亚基HIF-2α亚基及组成性亚基HIF-β亚基组成 [<xref ref-type="bibr" rid="hanspub.38261-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38261-ref4">4</xref>]。HIF-2α又称内皮PAS结构域包含蛋白-1 (endothelial PAS domain protein 1 EPAS1)、类HIF因子(HIF-like factor HLF)、HIF相关因子(HIF-related factor HRF)或PAS超家族成员2 (member of PAS superfamily 2 MOP2)，最初被认为是HIF-1α的同源异构体，由Tian等人首次克隆发现 [<xref ref-type="bibr" rid="hanspub.38261-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38261-ref6">6</xref>]。HIF-2α的氨基端含有bHLH结构域、PAS-A结构域和PAS-B结构域，分别与HIF-1α相应结构域同源性为99%、91%和96%。其羧基端含有反式激活结构域-C (transactivation domain terminal, TAD-C)、激活转录的反式激活结构域-N (transactivation domain-N terminal, TAD-N)和氧依赖降解结构域(oxygen-dependent degradation domain, ODDD)，TAD-C和TAD-N与HIF-1α相应结构域同源性分别为87%和81% [<xref ref-type="bibr" rid="hanspub.38261-ref7">7</xref>]。结构性亚基β亚基又称芳香烃受体核转运体(aryl hydrocarbon receptor nuclear translocator ARNT)，其表达量的多少不依赖细胞微环境中氧浓度的大小，可与多种bHLH-PAS蛋白发生异二聚反应 [<xref ref-type="bibr" rid="hanspub.38261-ref8">8</xref>]。</p></sec><sec id="s6_2"><title>2.2. HIF-2的调控</title><p>HIF-2的转录活性主要是通过调控HIF-2α亚基而调节的。HIF-2α亚基的表达受基因水平和蛋白水平的调节，但以蛋白质水平调节为主 [<xref ref-type="bibr" rid="hanspub.38261-ref9">9</xref>]。在常氧条件下，HIF-2α羧基端ODDD区域内特定脯氨酸残基被2-氧戊二酸和铁依赖性双加氧酶超家族成员脯氨酰羟化酶(prolyl hydroxylases, PHD)羟基化。羟基化的HIF-2α在von Hippel-Lindau蛋白协助下被E3泛素连接酶复合物捕获后泛素化，继而HIF-2α在蛋白酶体上被降解 [<xref ref-type="bibr" rid="hanspub.38261-ref10">10</xref>]。PHD对HIF-2α的羟基化作用需要分子氧的参与，因此当细胞内分子氧浓度降低时，PHD对HIF-2α的羟基化能力减弱，致使HIF-2α降解减少。累积的HIF-2α亚基与β亚基形成有转录活性的HIF-2异二聚体蛋白。此外，Krieg [<xref ref-type="bibr" rid="hanspub.38261-ref11">11</xref>] 等人研究发现在肾透明细胞癌细胞系中，当von Hippel-Lindau蛋白表达减少时不仅HIF-2α蛋白降解受到抑制，而且HIF-2αmRNA的表达也会增加。</p><p>HIF家族所调控的靶基因涉及众多方面，如缺氧代偿性反应、免疫反应、新生血管的生成调节、细胞外基质纤维化、转录调控、物质运输、能量代谢等。作为HIF家族中被研究最多的HIF-1和HIF-2既存在如血管内皮细胞生长因子(VEGF)、肾上腺髓质素(ADM)、葡萄糖载体蛋白1 (GLUT1)、白细胞介素6 (IL-6)、脂肪细胞分化相关蛋白(ADPR)等共同靶基因，也各自存在特异性靶基因 [<xref ref-type="bibr" rid="hanspub.38261-ref12">12</xref>]。有研究显示，与HIF-1α相比，HIF-2α可能调控着数量更大、功能更多样的靶基因 [<xref ref-type="bibr" rid="hanspub.38261-ref13">13</xref>]。Lin [<xref ref-type="bibr" rid="hanspub.38261-ref14">14</xref>] 等人研究发现HIF-1和HIF-2在急性和慢性缺氧下可能发挥不同的作用：HIF-1可能通过缺氧诱导HIF-1α蛋白稳定而参与急性缺氧反应，而HIF-2通过则通过增加HIF-2α的转录在细胞对慢性缺氧的适应中发挥更重要的作用，这提示我们HIF-2α在调节恶性肿瘤进展中可能有更重要的作用。</p></sec></sec><sec id="s7"><title>3. HIF-2与头颈部肿瘤</title><sec id="s7_1"><title>3.1. HIF-2与喉癌</title><p>近年来研究表明，HIF-1α在短时间(2~24小时)剧烈缺氧(&lt;0.1% O<sub>2</sub>)期间最活跃，而HIF-2α可能在较长时间的轻度缺氧(&lt;5% O<sub>2</sub>)中活跃。HIF-1α驱动对缺氧的最初反应，HIF-2随后在慢性缺氧暴露中起主要作用，这一现象在文献中被描述为HIF转换(HIF switch) [<xref ref-type="bibr" rid="hanspub.38261-ref15">15</xref>]。HIF转换在肾癌的发展过程中尤为明显，随着肿瘤分级的增加，HIF-1α表达逐渐转移到HIF-2α表达 [<xref ref-type="bibr" rid="hanspub.38261-ref16">16</xref>]。而Todor [<xref ref-type="bibr" rid="hanspub.38261-ref17">17</xref>] 等人通过对比分析63例喉鳞状细胞癌与正常组织中HIF-1α和HIF-2αmRNA表达差异发现在喉癌中缺乏HIF转换机制：在7例HIF-2α上调的T3-4期患者中，只有3名患者表现出明显的HIF转换。此外，他们的研究 [<xref ref-type="bibr" rid="hanspub.38261-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.38261-ref18">18</xref>] 还发现在喉癌组织中HIF-1αmRNA和血管内皮生长因子(Vascular Endothelial Growth Factor-A, VEGF-A) mRNA表达水平呈中度正相关(r = 0.392; P &lt; 0.005)，而HIF-2αmRNA则与血管内皮细胞生长因子受体1 (Vascular Endothelial Growth Factor Receptor 1, VEGFR-1)和血管内皮细胞生长因子受体2 (Vascular Endothelial Growth Factor Receptor 2, VEGFR-2) mRNA表达呈高度正相关(分别为r = 0.671, p &lt; 0.0005; r = 0.742, p &lt; 0.0005)。他们的研究结果提示HIF-1α和HIF-2α在喉鳞状细胞癌中协同促进肿瘤相关血管生成，推动喉癌进展。</p></sec><sec id="s7_2"><title>3.2. HIF-2与甲状腺肿瘤</title><p>HIF-2α在甲状腺肿瘤的研究结果尚存在争议。Wang [<xref ref-type="bibr" rid="hanspub.38261-ref19">19</xref>] 等人采用免疫组织化学方法和实时RT-PCR分析甲状腺乳头状癌(papillary thyroid carcinoma PTC)、结节性甲状腺肿和正常甲状腺组织中HIF-2α蛋白和mRNA的表达情况。他们发现在PTC中HIF-2α蛋白表达较结节性增生及正常甲状腺组织明显增高，且与淋巴结转移相关。而HIF-2αmRNA在三组中的表达无明显差异，且与淋巴结转移无关。J&#243;źwiak [<xref ref-type="bibr" rid="hanspub.38261-ref20">20</xref>] 等人通过分析结节性甲状腺肿(Nodular Goiter NG)、甲状腺滤泡性腺瘤(follicular thyroid adenoma, FTA)、PTC和滤泡状腺癌(follicular carcinoma FC)中HIF-2α蛋白和mRNA的表达差异时发现在不同甲状腺病变之间的HIF-2αmRNA水平虽无显著性差异，但PTC中HIF-2α蛋白免疫反应性较其他类型甲状腺病变显著增高。此外，PTC组内比较发现，与进展程度较低的I期相比，II/III期乳头状癌的HIF-2α蛋白和mRNA表达显著增高，但HIF-2α蛋白和mRNA表达的增高与淋巴结转移并无相关性。Liu [<xref ref-type="bibr" rid="hanspub.38261-ref21">21</xref>] 等人的研究显示在PTC中HIF-2αmRNA和蛋白的表达与正常对照组相比明显升高。HIF-2α高表达组比低表达组有着更高的临床分期、包膜侵犯发生率及淋巴结转移发生率。以上研究结果提示在PTC中存在着HIF-2α蛋白的高表达，然而关于在PTC中是否存在HIF-2αmRNA高表达以及HIF-2α的高表达是否会影响甲状腺肿瘤淋巴转移尚需进一步研究。</p></sec><sec id="s7_3"><title>3.3. HIF-2与其他头颈部肿瘤</title><p>Lim [<xref ref-type="bibr" rid="hanspub.38261-ref22">22</xref>] 等人通过免疫组化对比分析58例行手术治疗的口腔鳞状细胞癌组织及癌旁组织中HIF-2α蛋白表达差异发现HIF-2α在OSCC组中的表达较癌旁组织明显增高，且与临床分期相关。此外，虽然HIF-2α高表达组与低表达组在总生存率、肿瘤特异性生存率、无病生存率无显著差异，但HIF-2α高表达组较低表达组在2年内有明显的复发倾向。国内徐钢 [<xref ref-type="bibr" rid="hanspub.38261-ref23">23</xref>] 等人采用免疫组化SP法对比51例鼻咽癌组织和20例鼻咽炎性组织中HIF-2α的表达,发现HIF-2α的阳性表达率明显高于鼻咽炎性组织。在鼻咽癌组织中HIF-2α的表达与临床分期、T分期及颈淋巴结转移密切相关：中晚期鼻咽癌、T3/T4期及有淋巴结转移的鼻咽癌组织中HIF-2α阳性表达率较高。以上研究提示HIF-2α与口腔癌及鼻咽癌关系密切，其高表达可推动肿瘤进展，但具体机制尚需进一步研究。</p></sec></sec><sec id="s8"><title>4. 展望</title><p>综上所述，HIF-2作为低氧诱导因子家族中的重要一员，与喉癌、甲状腺肿瘤、鼻咽癌、口腔癌等多种头颈部恶性肿瘤发生发展相关。然而，目前关于HIF-2在头颈部肿瘤中相关研究仍然较少，且部分研究结果尚存在争议，需进一步研究证实。期待随着进一步深入研究，HIF-2在未来可被用作头颈部肿瘤可靠诊断标志物和将来用于癌症治疗的靶蛋白之一。</p></sec><sec id="s9"><title>文章引用</title><p>高 伟,李 钦. 缺氧诱导因子-2在头颈部肿瘤中的研究进展Research Progress of Hypoxia Inducible Factor-2 in Head and Neck Tumors[J]. 临床医学进展, 2020, 10(10): 2367-2371. https://doi.org/10.12677/ACM.2020.1010357</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38261-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李晓明. 正确把握头颈鳞状细胞癌临床治疗和研究的发展方向[J]. 中国耳鼻咽喉头颈外科, 2017, 24(11): 553-556.</mixed-citation></ref><ref id="hanspub.38261-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.38261-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Feng, Z., Zou, X., Chen, Y., et al. (2018) Modulation of HIF-2alpha PAS-B Domain Contributes to Physiological Responses. Proceedings of the National Academy of Sciences of the United States of America, 115, 13240-13245.  
&lt;br&gt;https://doi.org/10.1073/pnas.1810897115</mixed-citation></ref><ref id="hanspub.38261-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wu, D., Potluri, N., Lu, J., et al. (2015) Structural Integration in Hypoxia-Inducible Factors. Nature, 524, 303-308.  
&lt;br&gt;https://doi.org/10.1038/nature14883</mixed-citation></ref><ref id="hanspub.38261-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Patel, S.A. and Simon, M.C. (2008) Biology of Hypoxia-Inducible Factor-2alpha in Development and Disease. Cell Death &amp; Differentiation, 15, 628-634. &lt;br&gt;https://doi.org/10.1038/cdd.2008.17</mixed-citation></ref><ref id="hanspub.38261-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tian, H., Mcknight, S.L. and Russell, D.W. (1997) Endothelial PAS Domain Protein 1 (EPAS1), a Transcription Factor Selectively Expressed in Endothelial Cells. Genes &amp; Development, 11, 72-82. &lt;br&gt;https://doi.org/10.1101/gad.11.1.72</mixed-citation></ref><ref id="hanspub.38261-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lisy, K. and Peet, D.J. (2008) Turn Me On: Regulating HIF Transcriptional Activity. Cell Death &amp; Differentiation, 15, 642-649. &lt;br&gt;https://doi.org/10.1038/sj.cdd.4402315</mixed-citation></ref><ref id="hanspub.38261-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Semenza, G.L. (2017) A Compendium of Proteins That Interact with HIF-1alpha. Experimental Cell Research, 356, 128-135. &lt;br&gt;https://doi.org/10.1016/j.yexcr.2017.03.041</mixed-citation></ref><ref id="hanspub.38261-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李占全. 低氧诱导因子-2对红系造血和铁代谢调控相关蛋白作用的研究进展[J]. 国际输血及血液学杂志, 2010(6): 517-520.</mixed-citation></ref><ref id="hanspub.38261-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kiriakidis, S., Henze, A.T., Kruszynska-Ziaja, I., et al. (2015) Factor-Inhibiting HIF-1 (FIH-1) Is Required for Human Vascular Endothelial Cell Survival. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 29, 2814-2827. &lt;br&gt;https://doi.org/10.1096/fj.14-252379</mixed-citation></ref><ref id="hanspub.38261-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Krieg, M., Haas, R., Brauch, H., et al. (2000) Up-Regulation of Hypoxia-Inducible Factors HIF-1alpha and HIF-2alpha under Normoxic Conditions in Renal Carcinoma Cells by von Hippel-Lindau Tumor Suppressor Gene Loss of Function. Oncogene, 19, 5435-5443. &lt;br&gt;https://doi.org/10.1038/sj.onc.1203938</mixed-citation></ref><ref id="hanspub.38261-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">姚青, 李筠, 张鹏, 等. 缺氧诱导因子-1和缺氧诱导因子-2: 结构、功能及调节[J]. 生命科学, 2011, 23(8): 753-761.</mixed-citation></ref><ref id="hanspub.38261-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Downes, N.L., Laham-Karam, N., Kaikkonen, M.U., et al. (2018) Differential but Complementary HIF1α and HIF2α Transcriptional Regulation. Molecular Therapy: The Journal of the American Society of Gene Therapy, 26, 1735-1745.  
&lt;br&gt;https://doi.org/10.1016/j.ymthe.2018.05.004</mixed-citation></ref><ref id="hanspub.38261-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Q., Cong, X. and Yun, Z. (2011) Differential Hypoxic Regulation of Hypoxia-Inducible Factors 1alpha and 2alpha. Molecular Cancer Research, 9, 757-765. &lt;br&gt;https://doi.org/10.1158/1541-7786.MCR-11-0053</mixed-citation></ref><ref id="hanspub.38261-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bartoszewski, R., Moszyńska, A., Serocki, M., et al. (2019) Primary Endothelial Cell-Specific Regulation of Hypoxia-Inducible Factor (HIF)-1 and HIF-2 and Their Target Gene Expression Profiles during Hypoxia. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 33, 7929-7941.  
&lt;br&gt;https://doi.org/10.1096/fj.201802650RR</mixed-citation></ref><ref id="hanspub.38261-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Koh, M.Y. and Powis, G. (2012) Passing the Baton: The HIF Switch. Trends in Biochemical Sciences, 37, 364-372.  
&lt;br&gt;https://doi.org/10.1016/j.tibs.2012.06.004</mixed-citation></ref><ref id="hanspub.38261-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Popov, T.M., Goranova, T., Stancheva, G., et al. (2015) Relative Quantitative Expression of Hypoxia-Inducible Factor-1α, -2α and -3α, and Vascular Endothelial Growth Factor A in Laryngeal Carcinoma. Oncology Letters, 9, 2879.  
&lt;br&gt;https://doi.org/10.3892/ol.2015.3070</mixed-citation></ref><ref id="hanspub.38261-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Popov, T.M., Stancheva, G., Goranova, T.E., et al. (2016) Strong Correlation between mRNA Expression Levels of HIF-2α, VEGFR1, VEGFR2 and MMP2 in Laryngeal Carcinoma. Pathology &amp; Oncology Research, 22, 741-746.  
&lt;br&gt;https://doi.org/10.1007/s12253-016-0059-4</mixed-citation></ref><ref id="hanspub.38261-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Wang, N., Luo, H.J., Yin, G.B., et al. (2013) Overexpression of HIF-2α, TWIST, and CXCR4 Is Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma. Clinical &amp; Developmental Immunology, 2013, Article ID: 589423. &lt;br&gt;https://doi.org/10.1155/2013/589423</mixed-citation></ref><ref id="hanspub.38261-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">jóźwiak, P., Ciesielski, P., Zaczek, A., et al. (2017) Expression of Hypoxia Inducible Factor 1α and 2α and Its Association with Vitamin C Level in Thyroid Lesions. Journal of Biomedical Science, 24, Article No. 83.  
&lt;br&gt;https://doi.org/10.1186/s12929-017-0388-y</mixed-citation></ref><ref id="hanspub.38261-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.M., Ying, S.P., Huang, Y.R., et al. (2016) Expression of HIF-1α and HIF-2α Correlates to Biological and Clinical Significance in Papillary Thyroid Carcinoma. World Journal of Surgical Oncology, 14, 30.  
&lt;br&gt;https://doi.org/10.1186/s12957-016-0785-9</mixed-citation></ref><ref id="hanspub.38261-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lim, E., Kuo, C.C., Tu, H.F., et al. (2017) The Prognosis Outcome of Oral Squamous Cell Carcinoma Using HIF-2α. Journal of the Chinese Medical Association: JCMA, 80, 651-656. &lt;br&gt;https://doi.org/10.1016/j.jcma.2017.06.005</mixed-citation></ref><ref id="hanspub.38261-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">徐钢, 李先明, 刘湘园, 吴冬, 闫茂生, 杨东. 鼻咽癌患者中缺氧诱导因子2α表达的临床意义[J]. 癌症进展, 2012, 10(4): 392-395.</mixed-citation></ref></ref-list></back></article>